Do you escalate to 7.2 mg semaglutide in a patient with obesity who has not achieved their weight loss goal on the 2.4 mg dose despite the increased risk of dysesthesia at the higher dose?

What is your preferred next step in a patient with obesity who has not achieved their weight loss goal on semaglutide 2.4 mg?

• Escalate to semaglutide 7.2 mg despite the higher side effect burden
• Switch to tirzepatide given superior weight loss data and approved status
• Add an adjunctive weight loss medication rather than changing the GLP-1 regimen
• Reassess lifestyle and behavioral interventions before changing pharmacotherapy
• Continue semaglutide 2.4 mg and reassess — the patient may not yet have reached their maximum response
• Other